Effect of hyperglycemia and hyperinsulinemia on the response of IL-6, TNF-α, and FFAs to low-dose endotoxemia in humans

American Journal of Physiology - Endocrinology and Metabolism

Volumn 286, Issue 5 49-5, 2004, Pages

  Krogh Madsen, Rikke ^a   Møller, Kirsten ^a   Dela, Flemming ^b   Kronborg, Gitte ^a   Jauffred, Sune ^a   Pedersen, Bente Klarlund ^a,b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Endotoxin; Free fatty acids; Inflammation; Insulin

Indexed keywords

ENDOTOXIN; FATTY ACID; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; CYTOKINE PRODUCTION; ENDOTOXEMIA; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; HYPERINSULINEMIA; INFLAMMATION; INSULIN TREATMENT; LEUKOCYTE; LYMPHOCYTE COUNT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEPSIS;

ADULT; BLOOD GLUCOSE; ENDOTOXEMIA; FATTY ACIDS, NONESTERIFIED; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; INSULIN; INTERLEUKIN-6; LEUKOCYTE COUNT; MALE; REFERENCE VALUES; SERUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1942454244     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00468.2003     Document Type: Article

References (55)

1. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R, Levy H, Baughman R, Rumbak M, Light RB, Poole L, Allred R, Constant J, Pennington J, and Porter S. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 351: 929-933, 1998.
2. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, Pennington JE, and Wherry JC. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial TNF-alpha. MAb Sepsis Study Group. JAMA 273: 934-941, 1995.
3. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaut P, and Bellissant E. Effect of treatment with low doses of hydrocortisone and fluorocortisone on mortality in patients with septic shock. JAMA 288: 862-871, 2002.
4. Arner P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes Metab Res Rev 18, Suppl 2: S5-S9, 2002.
5. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, and Fisher CJ Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709, 2001.
6. Bessey PQ, Brooks DC, Black PR, Aoki TT, and Wilmore DW. Epinephrine acutely mediates skeletal muscle insulin resistance. Surgery 94: 172-179, 1983.
7. Boden G. Interaction between free fatty acids and glucose metabolism. Curr Opin Clin Nutr Metab Care 5: 545-549, 2002.
8. Boden G and Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 32, Suppl 3: 14-23, 2002.
9. Connolly CC, Steiner KE, Stevenson RW, Neal DW, Williams PE, Alberti KG, and Cherrington AD. Regulation of glucose metabolism by norepinephrine in conscious dogs. Am J Physiol Endocrinol Metab 261: E764-E772, 1991.
10. Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 60: 349-356, 2001.
11. DeFronzo RA, Tobin JD, and Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab Gastrointest Physiol 237: E214-E223, 1979.
12. Dimitriadis G, Leighton B, Parry-Billings M, Sasson S, Young M, Krause U, Bevan S, Piva T, Wegener G, and Newsholme EA. Effects of glucocorticoid excess on the sensitivity of glucose transport and metabolism to insulin in rat skeletal muscle. Biochem J 321: 707-712, 1997.
13. Dominici FP, Cifone D, Bartke A, and Turyn D. Alterations in the early steps of the insulin-signaling system in skeletal muscle of GH-transgenic mice. Am J Physiol Endocrinol Metab 277: E447-E454, 1999.
14. Elin RJ, Wolff SM, McAdam KP, Chedid L, Audibert F, Bernard C, and Oberling F. Properties of reference Escherichia coli endotoxin and its phthalylated derivative in humans. J Infect Dis 144: 329-336, 1981.
15. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, and Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106: 2067-2072, 2002.
16. Evans JL, Goldfine ID, Maddux BA, and Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23: 599-622, 2002.
17. Feingold KR, Doerrler W, Dinarello CA, Fiers W, and Grunfeld C. Stimulation of lipolysis in cultured fat cells by tumor necrosis factor, interleukin-1, and the interferons is blocked by inhibition of prostaglandin synthesis. Endocrinology 130: 10-16, 1992.
18. Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett 285: 199-212, 1991.
19. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, and Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334: 1697-1702, 1996.
20. Fryburg DA, Gelfand RA, Jahn LA, Oliveras D, Sherwin RS, Sacca L, and Barrett EJ. Effects of epinephrine on human muscle glucose and protein metabolism. Am J Physiol Endocrinol Metab 268: E55-E59, 1995.
21. Geerlings SE and Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 26: 259-265, 1999.
22. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 245: 621-625, 1999.
23. Krabbe KS, Bruunsgaard H, Qvist J, Fonsmark L, Moller K, Hansen CM, Skinhoj P, and Pedersen BK. Activated T lymphocytes disappear from circulation during endotoxemia in humans. Clin Diagn Lab Immunol 9: 731-735, 2002.
24. Krogh-Madsen R, Plomgaard P, Keller P, Keller C, and Pedersen BK. Insulin stimulates interleukin-6 and tumor necrosis factor-α gene expression in human subcutaneous adipose tissue. Am J Physiol Endocrinol Metab 286: E234-E238, 2004.
25. Lind L and Lithell H. Impaired glucose and lipid metabolism seen in intensive care patients is related to severity of illness and survival. Clin Intensive Care 5: 100-105, 1994.
26. Lyngso D, Simonsen L, and Bulow J. Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. J Physiol 543: 379-386, 2002.
27. Matthys P, Mitera T, Heremans H, Van Damme J, and Billiau A. Anti-gamma interferon and anti-interleukin-6 antibodies affect staphylococcal enterotoxin B-induced weight loss, hypoglycemia, and cytokine release in D-galactosamine-sensitized and unsensitized mice. Infect Immunol 63: 1158-1164, 1995.
28. McCloskey RV, Straube RC, Sanders C, Smith SM, and Smith CR. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 121: 1-5, 1994.
29. McCowen KC, Malhotra A, and Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin 17: 107-124, 2001.
30. Minneci P, Deans K, Natanson C, and Eichacker PQ. Increasing the efficacy of anti-inflammatory agents used in the treatment of sepsis. Eur J Clin Microbiol Infect Dis 22: 1-9, 2003.
31. Mizock BA. Metabolic derangements in sepsis and septic shock. Crit Care Clin 16: 319-336, 2000.
32. Mizuhara H, O'Neill E, Seki N, Ogawa T, Kusunoki C, Otsuka K, Satoh S, Niwa M, Senoh H, and Fujiwara H. T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med 179: 1529-1537, 1994.
33. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 11: 212-217, 2000.
34. Mullington J, Korth C, Hermann DM, Orth A, Galanos C, Holsboer F, and Pollmacher T. Dose-dependent effects of endotoxin on human sleep. Am J Physiol Regal Integr Comp Physiol 278: R947-R955, 2000.
35. Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, and Seneff M. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 25: 1115-1124, 1997.
36. Parker SJ and Watkins PE. Experimental models of gram-negative sepsis. Br J Surg 88: 22-30, 2001.
37. Qvigstad E, Mostad IL, Bjerve KS, and Grill VE. Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects. Am J Physiol Endocrinol Metab 284: E129-E137, 2003.
38. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, and Pollmacher T. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 58: 445-452, 2001.
39. Ruan H, Miles PD, Ladd CM, Ross K, Golub TR, Olefsky JM, and Lodish HF. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. Diabetes 51: 3176-3188, 2002.
40. Sakurai Y, Zhang XU, and Wolfe RR. Short-term effects of tumor necrosis factor on energy and substrate metabolism in dogs. J Clin Invest 91: 2437-2445, 1993.
41. Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ, Strassmann PG, and Wajchenberg BL. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 48: 1836-1841, 1999.
42. Santos AA and Wilmore DW. The systemic inflammatory response: perspective of human endotoxemia. Shock 6, Suppl I: S50-S56, 1996.
43. Segerlantz M, Bramnert M, Manhem P, Laurila E, and Groop LC. Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults. J Clin Endocrinol Metab 86: 5813-5818, 2001.
44. Sherwin RS and Sacca L. Effect of epinephrine on glucose metabolism in humans: contribution of the liver. Am J Physiol Endocrinol Metab 247: E157-E165, 1984.
45. Soop M, Duxbury H, Agwunobi AO, Gibson JM, Hopkins SJ, Childs C, Cooper RG, Maycock P, Little RA, and Carlson GL. Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans. Am J Physiol Endocrinol Metab 282: E1276-E1285, 2002.
46. Spitzer JJ, Bagby GJ, Meszaros K, and Lang CH. Alterations in lipid and carbohydrate metabolism in sepsis. J Parenter Enteral Nutr 12: 53S-58S, 1988.
47. Starkie R, Ostrowski SR, Jauffred S, Febbraio M, and Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 17: 884-886, 2003.
48. Steensberg A, Fischer CP, Keller C, Moller K, and Pedersen BK. IL-6 enhances plasma IL-Ira, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab 285: E433-E437, 2003.
49. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, and Bouillon R. Intensive insulin therapy in the critically ill patients. N Engl J Med 345: 1359-1367, 2001.
50. Van der Pool T, Romijn JA, Endert E, Borm JJ, Buller HR, and Sauerwein HP. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol Endocrinol Metab 261: E457-E465, 1991.
51. Van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, Hiscock N, Moller K, Saltin B, Febbraio MA, and Pedersen BK. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88: 3005-3010, 2003.
52. Von Kanel R, Mills PJ, and Dimsdale JE. Short-term hyperglycemia induces lymphopenia and lymphocyte subset redistribution. Life Sci 69: 255-262, 2001.
53. Wichterman KA, Baue AE, and Chaudry IH. Sepsis and septic shock - a review of laboratory models and a proposal. J Surg Res 29: 189-201, 1980.
54. Yu WK, Li WQ, Li N, and Li JS. Influence of acute hyperglycemia in human sepsis on inflammatory cytokine and counterregulatory hormone concentrations. World J Gastroenterol 9: 1824-1827, 2003.
55. Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NN, Allen EI, Berger HJ, Knatterud GL, LoBuglio AF, and Smith CK. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 324: 429-436, 1991.